# Efficacy of Mirabegron Versus Tamsulosin Versus Solifenacin for Treatment of Ureteral Stents-Related Symptoms

> **NCT04325880** · PHASE3 · UNKNOWN · sponsor: **Mansoura University** · enrollment: 240 (estimated)

## Conditions studied

- Ureteral Stent
- Stent Related Symptoms

## Interventions

- **DRUG:** Mirabegron 50 MG
- **DRUG:** Tamsulosin
- **DRUG:** Solifenacin Succinate 10 MG
- **DRUG:** Placebo oral tablet

## Key facts

- **NCT ID:** NCT04325880
- **Lead sponsor:** Mansoura University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-12-01
- **Primary completion:** 2022-06-01
- **Final completion:** 2022-07-01
- **Target enrollment:** 240 (ESTIMATED)
- **Last updated:** 2021-11-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04325880

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04325880, "Efficacy of Mirabegron Versus Tamsulosin Versus Solifenacin for Treatment of Ureteral Stents-Related Symptoms". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04325880. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*